Selected research
Industry Research
Flu (Influenza) Vaccine Industry Research Report 2026
Market perspective
The global Flu (Influenza) Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Flu (Influenza) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Flu (Influenza) Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Flu (Influenza) Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Flu (Influenza) Vaccine include Adimmune, Aimei Hissen, Aleph Biomedical, CCBIO, Changsheng Biological, Hualan Bio, Simcere Vaxtec, SINOVAC and SIOBP, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Flu (Influenza) Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Flu (Influenza) Vaccine Market by Company
Adimmune
Aimei Hissen
Aleph Biomedical
CCBIO
Changsheng Biological
Hualan Bio
Simcere Vaxtec
SINOVAC
SIOBP
Tianyuan Bio-pharma(Novartis)
ZYAK
GSK
SANOFI
Flu (Influenza) Vaccine Segment by Type
Subunit Influenza Vaccine
Quadrivalent Influenza Vaccine
Split Influenza Vaccine
Pandemic Influenza Vaccine
Flu (Influenza) Vaccine Segment by Application
For Children (6 months to 3 years)
For Adults and Children over 3 years
Flu (Influenza) Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Flu (Influenza) Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Flu (Influenza) Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Flu (Influenza) Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Flu (Influenza) Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Flu (Influenza) Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Flu (Influenza) Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Subunit Influenza Vaccine
- Quadrivalent Influenza Vaccine
- Split Influenza Vaccine
- Pandemic Influenza Vaccine
Applications
- For Children (6 months to 3 years)
- For Adults and Children over 3 years
Companies covered
- Adimmune
- Aimei Hissen
- Aleph Biomedical
- CCBIO
- Changsheng Biological
- Hualan Bio
- Simcere Vaxtec
- SINOVAC
- SIOBP
- Tianyuan Bio-pharma(Novartis)
- ZYAK
- GSK
- SANOFI
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Flu (Influenza) Vaccine Market Size (2021-2032)
- 2.2.2 Global Flu (Influenza) Vaccine Sales (2021-2032)
- 2.2.3 Global Flu (Influenza) Vaccine Market Average Price (2021-2032)
- 2.3 Flu (Influenza) Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Subunit Influenza Vaccine
- 2.3.3 Quadrivalent Influenza Vaccine
- 2.3.4 Split Influenza Vaccine
- 2.3.5 Pandemic Influenza Vaccine
- 2.4 Flu (Influenza) Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 For Children (6 months to 3 years)
- 2.4.3 For Adults and Children over 3 years
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Flu (Influenza) Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Flu (Influenza) Vaccine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Flu (Influenza) Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Flu (Influenza) Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Flu (Influenza) Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Flu (Influenza) Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Flu (Influenza) Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Flu (Influenza) Vaccine, Established Date
- 3.9 Global Flu (Influenza) Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Adimmune
- 4.1.1 Adimmune Company Information
- 4.1.2 Adimmune Business Overview
- 4.1.3 Adimmune Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Adimmune Flu (Influenza) Vaccine Product Portfolio
- 4.1.5 Adimmune Recent Developments
- 4.2 Aimei Hissen
- 4.2.1 Aimei Hissen Company Information
- 4.2.2 Aimei Hissen Business Overview
- 4.2.3 Aimei Hissen Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Aimei Hissen Flu (Influenza) Vaccine Product Portfolio
- 4.2.5 Aimei Hissen Recent Developments
- 4.3 Aleph Biomedical
- 4.3.1 Aleph Biomedical Company Information
- 4.3.2 Aleph Biomedical Business Overview
- 4.3.3 Aleph Biomedical Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Aleph Biomedical Flu (Influenza) Vaccine Product Portfolio
- 4.3.5 Aleph Biomedical Recent Developments
- 4.4 CCBIO
- 4.4.1 CCBIO Company Information
- 4.4.2 CCBIO Business Overview
- 4.4.3 CCBIO Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 CCBIO Flu (Influenza) Vaccine Product Portfolio
- 4.4.5 CCBIO Recent Developments
- 4.5 Changsheng Biological
- 4.5.1 Changsheng Biological Company Information
- 4.5.2 Changsheng Biological Business Overview
- 4.5.3 Changsheng Biological Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Changsheng Biological Flu (Influenza) Vaccine Product Portfolio
- 4.5.5 Changsheng Biological Recent Developments
- 4.6 Hualan Bio
- 4.6.1 Hualan Bio Company Information
- 4.6.2 Hualan Bio Business Overview
- 4.6.3 Hualan Bio Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hualan Bio Flu (Influenza) Vaccine Product Portfolio
- 4.6.5 Hualan Bio Recent Developments
- 4.7 Simcere Vaxtec
- 4.7.1 Simcere Vaxtec Company Information
- 4.7.2 Simcere Vaxtec Business Overview
- 4.7.3 Simcere Vaxtec Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Simcere Vaxtec Flu (Influenza) Vaccine Product Portfolio
- 4.7.5 Simcere Vaxtec Recent Developments
- 4.8 SINOVAC
- 4.8.1 SINOVAC Company Information
- 4.8.2 SINOVAC Business Overview
- 4.8.3 SINOVAC Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 SINOVAC Flu (Influenza) Vaccine Product Portfolio
- 4.8.5 SINOVAC Recent Developments
- 4.9 SIOBP
- 4.9.1 SIOBP Company Information
- 4.9.2 SIOBP Business Overview
- 4.9.3 SIOBP Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 SIOBP Flu (Influenza) Vaccine Product Portfolio
- 4.9.5 SIOBP Recent Developments
- 4.10 Tianyuan Bio-pharma(Novartis)
- 4.10.1 Tianyuan Bio-pharma(Novartis) Company Information
- 4.10.2 Tianyuan Bio-pharma(Novartis) Business Overview
- 4.10.3 Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Product Portfolio
- 4.10.5 Tianyuan Bio-pharma(Novartis) Recent Developments
- 4.11 ZYAK
- 4.11.1 ZYAK Company Information
- 4.11.2 ZYAK Business Overview
- 4.11.3 ZYAK Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 ZYAK Flu (Influenza) Vaccine Product Portfolio
- 4.11.5 ZYAK Recent Developments
- 4.12 GSK
- 4.12.1 GSK Company Information
- 4.12.2 GSK Business Overview
- 4.12.3 GSK Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 GSK Flu (Influenza) Vaccine Product Portfolio
- 4.12.5 GSK Recent Developments
- 4.13 SANOFI
- 4.13.1 SANOFI Company Information
- 4.13.2 SANOFI Business Overview
- 4.13.3 SANOFI Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 SANOFI Flu (Influenza) Vaccine Product Portfolio
- 4.13.5 SANOFI Recent Developments
5 Global Flu (Influenza) Vaccine Market Scenario by Region
- 5.1 Global Flu (Influenza) Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Flu (Influenza) Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Flu (Influenza) Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Flu (Influenza) Vaccine Sales by Region: 2027-2032
- 5.3 Global Flu (Influenza) Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Flu (Influenza) Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Flu (Influenza) Vaccine Revenue by Region: 2027-2032
- 5.4 North America Flu (Influenza) Vaccine Market Facts & Figures by Country
- 5.4.1 North America Flu (Influenza) Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Flu (Influenza) Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Flu (Influenza) Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Flu (Influenza) Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Flu (Influenza) Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Flu (Influenza) Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Flu (Influenza) Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Flu (Influenza) Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Flu (Influenza) Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Flu (Influenza) Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Flu (Influenza) Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Flu (Influenza) Vaccine Market Facts & Figures by Country
- 5.7.1 South America Flu (Influenza) Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Flu (Influenza) Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Flu (Influenza) Vaccine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Flu (Influenza) Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Flu (Influenza) Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Flu (Influenza) Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Flu (Influenza) Vaccine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Flu (Influenza) Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Flu (Influenza) Vaccine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Flu (Influenza) Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Flu (Influenza) Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Flu (Influenza) Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Flu (Influenza) Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Flu (Influenza) Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Flu (Influenza) Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Flu (Influenza) Vaccine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Flu (Influenza) Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Flu (Influenza) Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Flu (Influenza) Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Flu (Influenza) Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Flu (Influenza) Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Flu (Influenza) Vaccine Value Chain Analysis
- 8.1.1 Flu (Influenza) Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Flu (Influenza) Vaccine Production Mode & Process
- 8.2 Flu (Influenza) Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Flu (Influenza) Vaccine Distributors
- 8.2.3 Flu (Influenza) Vaccine Customers
9 Global Flu (Influenza) Vaccine Analyzing Market Dynamics
- 9.1 Flu (Influenza) Vaccine Industry Trends
- 9.2 Flu (Influenza) Vaccine Industry Drivers
- 9.3 Flu (Influenza) Vaccine Industry Opportunities and Challenges
- 9.4 Flu (Influenza) Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst